Raymond James Financial Inc. Invests $4.79 Million in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Raymond James Financial Inc. purchased a new position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 411,077 shares of the company's stock, valued at approximately $4,793,000. Raymond James Financial Inc. owned about 0.40% of Intellia Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently modified their holdings of the company. Barclays PLC increased its stake in Intellia Therapeutics by 17.7% during the 3rd quarter. Barclays PLC now owns 292,795 shares of the company's stock valued at $6,017,000 after purchasing an additional 44,022 shares in the last quarter. Virtu Financial LLC purchased a new position in Intellia Therapeutics in the 3rd quarter worth $417,000. Franklin Resources Inc. lifted its position in Intellia Therapeutics by 10.3% during the 3rd quarter. Franklin Resources Inc. now owns 16,405 shares of the company's stock worth $320,000 after acquiring an additional 1,538 shares during the period. Green Alpha Advisors LLC purchased a new stake in Intellia Therapeutics during the 4th quarter valued at about $138,000. Finally, AdvisorNet Financial Inc increased its holdings in shares of Intellia Therapeutics by 96.4% in the fourth quarter. AdvisorNet Financial Inc now owns 10,085 shares of the company's stock valued at $118,000 after purchasing an additional 4,950 shares during the period. Institutional investors and hedge funds own 88.77% of the company's stock.

Intellia Therapeutics Stock Performance

Shares of NTLA traded down $0.28 during mid-day trading on Tuesday, hitting $8.20. 2,849,221 shares of the company were exchanged, compared to its average volume of 2,390,805. Intellia Therapeutics, Inc. has a 1-year low of $5.90 and a 1-year high of $28.18. The stock has a market cap of $848.84 million, a price-to-earnings ratio of -1.51 and a beta of 2.23. The company has a 50 day moving average of $8.59 and a 200-day moving average of $11.70.

Analyst Ratings Changes

NTLA has been the topic of a number of recent research reports. Barclays dropped their target price on Intellia Therapeutics from $55.00 to $26.00 and set an "overweight" rating on the stock in a research report on Friday, February 28th. BMO Capital Markets cut their price objective on shares of Intellia Therapeutics from $70.00 to $50.00 and set an "outperform" rating on the stock in a research note on Friday, January 10th. The Goldman Sachs Group restated a "sell" rating and set a $9.00 target price on shares of Intellia Therapeutics in a research report on Friday, February 28th. Wedbush reaffirmed a "neutral" rating and set a $10.00 price target (down from $14.00) on shares of Intellia Therapeutics in a research report on Friday, January 10th. Finally, JPMorgan Chase & Co. reissued a "neutral" rating and issued a $13.00 price objective (down previously from $45.00) on shares of Intellia Therapeutics in a report on Friday, February 28th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $36.68.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.